| Name | Pafuramidine |
| Description | Pafuramidine (DB289) is an experimental prodrug of the orally active metabolite DB75, a potent antiparasitic compound with anti-malarial activity used in the study of parasitic infections and sleeping sickness. |
| In vitro | The results of this investigation suggest that DB75 inhibits mitochondrial function. Yeast cells relying upon mitochondrial metabolism for energy production are especially sensitive to DB75 [1]. |
| In vivo | In monkeys infected with Trypanosoma cruzi, treatment with oral Pafuramidine at doses of 1, 3 and 10 mg/kg for five consecutive days on the seventh day post-infection (p.i.) of early infection showed that Pafuramidine treatment benefited most of the monkeys, and at the end of the experiment all monkeys except group 1 had improved body weights and PCVs, and in some individuals parasitemia and cerebrospinal fluid parasitemia had cleared. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 33.33 mg/mL (91.47 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.49 mM), Sonication is recommended.
|
| Keywords | Pafuramidine | P. falciparum | DB-289 | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Ampicillin sodium | Kanamycin sulfate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Metronidazole | 2-Amino-2-methyl-1-propanol | Doxycycline | Penicillin G sodium salt | Fenpyroximate | Ethyl acetoacetate |
| Related Compound Libraries | Anti-Parasitic Compound Library | Bioactive Compound Library | ReFRAME Related Library | Antibiotics Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
United States
